Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01569464 · ClinicalTrials.gov registry record · Phase 3
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT01569464 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 150 participants.
The verdict
NCT01569464, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of the study is to show that Rotigotine improves Restless Legs Syndrome (RLS) symptoms in subjects with moderate to severe RLS during both day and evening.
Interventions
- OTHER Placebo
- DRUG Rotigotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01569464
The ClinicalTrials.gov registry entry for NCT01569464 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01569464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01569464 about?
NCT01569464 is a clinical study titled "Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)". The purpose of the study is to show that Rotigotine improves Restless Legs Syndrome (RLS) symptoms in subjects with moderate to severe RLS during both day and evening.
What is the current status of trial NCT01569464?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2012-03. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01569464?
The interventions under investigation include: Placebo (OTHER), Rotigotine (DRUG).
Who is sponsoring clinical trial NCT01569464?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.